HC Wainwright Forecasts Pelthos Therapeutics Q1 Earnings

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) – Equities researchers at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for shares of Pelthos Therapeutics in a note issued to investors on Thursday, March 19th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($4.49) per share for the quarter, down from their previous estimate of ($1.88). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. HC Wainwright also issued estimates for Pelthos Therapeutics’ Q2 2026 earnings at ($3.48) EPS, Q3 2026 earnings at ($2.29) EPS, Q4 2026 earnings at ($2.60) EPS, FY2026 earnings at ($14.39) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at $10.86 EPS, FY2029 earnings at $15.42 EPS and FY2030 earnings at $18.79 EPS.

A number of other analysts have also recently weighed in on the company. Roth Mkm lowered their price target on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Zacks Research cut Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, January 30th. Oppenheimer boosted their target price on shares of Pelthos Therapeutics from $60.00 to $62.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Piper Sandler began coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 target price for the company. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Pelthos Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $56.25.

Pelthos Therapeutics Price Performance

Pelthos Therapeutics stock opened at $20.74 on Monday. The stock’s 50 day moving average is $23.28. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.05 and a quick ratio of 1.15. The company has a market cap of $69.69 million, a P/E ratio of -1.00 and a beta of 3.86. Pelthos Therapeutics has a one year low of $9.00 and a one year high of $54.29.

Institutional Trading of Pelthos Therapeutics

Large investors have recently made changes to their positions in the business. Persistent Asset Partners Ltd increased its stake in shares of Pelthos Therapeutics by 150.0% in the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after buying an additional 3,604 shares in the last quarter. Millennium Management LLC acquired a new position in Pelthos Therapeutics during the 4th quarter worth about $343,000. Geode Capital Management LLC grew its holdings in Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after acquiring an additional 3,295 shares during the last quarter. Knott David M Jr grew its holdings in Pelthos Therapeutics by 215.5% during the 4th quarter. Knott David M Jr now owns 19,281 shares of the company’s stock worth $598,000 after acquiring an additional 13,169 shares during the last quarter. Finally, Diadema Partners LP increased its position in Pelthos Therapeutics by 138.1% in the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after acquiring an additional 14,502 shares in the last quarter. Institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics News Roundup

Here are the key news stories impacting Pelthos Therapeutics this week:

• Positive Sentiment: HC Wainwright raised long‑range earnings power — materially higher EPS forecasts for FY2028–FY2030 (FY2028 to $10.86, FY2029 to $15.42, FY2030 to $18.79) imply strong upside potential if the company executes on its development plan. This is the key reason the firm retained a Buy rating and $60 target.
• Neutral Sentiment: HC Wainwright maintained its “Buy” rating and $60 price target despite the near‑term cuts, signaling the firm still views Pelthos as a multi‑year growth/return story rather than a cut‑and‑run situation. Article Title
• Negative Sentiment: Significant downward revisions to 2026 guidance: HC Wainwright lowered Q1–Q4 2026 EPS (Q1 to ($4.49), Q2 to ($3.48), Q3 to ($2.29), Q4 to ($2.60)) and cut FY2026 from ($6.31) to ($14.39). Those large near‑term cuts increase uncertainty around upcoming cash burn, milestones and financing needs and are the most immediate negative catalyst driving today’s sell‑off. Article Title

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).